Alpharma withdraws painkiller NDA

Alpharma has withdrawn its NDA for Embeda, its extended-release painkiller. While the company's drug qualified for priority review, Alpharma said that "certain technical issues around data presentation" prevented the FDA from evaluating the drug in the six month review time. There were no details on exactly what those technical issues were. Alpharma said it plans to quickly resolve the issues, re-submit the NDA and launch the drug in the first quarter of 2009.

In its most recent Phase III trial, Embeda demonstrated significant pain relief. The painkiller is designed to be effective when taken as directed, but if tampered with by a drug abuser, the feeling of euphoria is dampened.

- see Alpharma's release

Related Articles:
Alpharma touts Phase III pain drug data
Alpharma sub inks $202M deal for pain drug
Alpharma to proceed with painkiller trial
Investors bid up Alpharma stock on rumors of a sale

Suggested Articles

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.